Highlights
- Market Cap
- $35.33B
- Enterprise Value
- $50.69B
- EPS (TTM)
- $1.21
- PE Ratio
- 24.93
- PEG Ratio
- 0.19
- Total Revenue (TTM)
- $17.26B
- Gross Profit (TTM)
- $8.94B
- EBITDA (TTM)
- $3.80B
- Year Range
- $12.47 - $37.35
- Target Price
- $36.83
- ROA (TTM)
- 3.46%
- ROE (TTM)
- 17.80%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Teva Pharmaceutical Industries Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Teva Pharmaceutical Industries Limited (TEVA) has returned -3.49% so far this year and 95.97% over the past 12 months. Over the last ten years, TEVA has returned -5.25% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Teva Pharmaceutical Industries Limited
- 1D
- 6.24%
- 1M
- -11.05%
- YTD
- -3.49%
- 6M
- 49.11%
- 1Y
- 95.97%
- 3Y*
- 50.42%
- 5Y*
- 21.28%
- 10Y*
- -5.25%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 26, 1990, TEVA's average daily return is +0.07%, while the average monthly return is +1.49%. At this rate, your investment would double in approximately 3.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 1991 with a return of +42.1%, while the worst month was Aug 2017 at -50.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.
On a daily basis, TEVA closed higher 48% of trading days. The best single day was Jul 27, 2022 with a return of +28.4%, while the worst single day was Aug 3, 2017 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.20% | -0.65% | -11.05% | -3.49% | |||||||||
| 2025 | -19.56% | -7.16% | -6.62% | 0.91% | 8.19% | -0.12% | -7.82% | 18.96% | 9.90% | 1.39% | 31.30% | 16.07% | 41.61% |
| 2024 | 15.90% | 8.68% | 7.30% | -0.43% | 20.50% | -4.02% | 7.26% | 8.26% | -4.50% | 2.33% | -9.00% | 31.35% | 111.11% |
| 2023 | 15.57% | -5.98% | -10.70% | -1.36% | -17.53% | 4.58% | 11.55% | 16.19% | 4.51% | -15.88% | 14.45% | 6.31% | 14.47% |
| 2022 | 5.24% | -3.56% | 15.50% | -7.24% | 4.48% | -17.36% | 24.73% | -3.62% | -10.73% | 10.53% | -1.68% | 3.99% | 13.86% |
| 2021 | 22.07% | -8.66% | 7.25% | -7.28% | -2.80% | -4.81% | -2.53% | -2.38% | 3.40% | -10.27% | -5.61% | -2.91% | -16.99% |
Benchmark Metrics
Teva Pharmaceutical Industries Limited has an annualized alpha of 12.14%, beta of 0.73, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since March 27, 1990.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (68.57%) than losses (44.90%) — typical of diversified or defensive assets.
- R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.14%
- Beta
- 0.73
- R²
- 0.12
- Upside Capture
- 68.57%
- Downside Capture
- 44.90%
Return for Risk
Risk / Return Rank
TEVA ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and compare them to a chosen benchmark (S&P 500 Index).
| TEVA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.29 | 0.90 | +1.39 |
Sortino ratioReturn per unit of downside risk | 3.07 | 1.39 | +1.69 |
Omega ratioGain probability vs. loss probability | 1.41 | 1.21 | +0.20 |
Calmar ratioReturn relative to maximum drawdown | 4.58 | 1.40 | +3.18 |
Martin ratioReturn relative to average drawdown | 13.38 | 6.61 | +6.78 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore TEVA risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Teva Pharmaceutical Industries Limited provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.74 | $1.16 | $1.16 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Monthly Dividends
The table displays the monthly dividend distributions for Teva Pharmaceutical Industries Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Teva Pharmaceutical Industries Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Teva Pharmaceutical Industries Limited was 90.89%, occurring on Aug 15, 2019. The portfolio has not yet recovered.
The current Teva Pharmaceutical Industries Limited drawdown is 55.48%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.89% | Jul 28, 2015 | 1021 | Aug 15, 2019 | — | — | — |
| -52.14% | Jun 23, 1997 | 265 | Jul 10, 1998 | 371 | Dec 29, 1999 | 636 |
| -44.12% | Mar 24, 2010 | 381 | Sep 23, 2011 | 837 | Jan 23, 2015 | 1218 |
| -36.77% | Feb 25, 1994 | 220 | Jan 10, 1995 | 66 | Apr 13, 1995 | 286 |
| -36.5% | May 15, 1996 | 64 | Aug 14, 1996 | 95 | Dec 30, 1996 | 159 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Teva Pharmaceutical Industries Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Teva Pharmaceutical Industries Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TEVA, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/E ratio of 24.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TEVA compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TEVA currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TEVA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/S ratio of 2.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TEVA in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/B value of 4.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |